Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers.

Authors:
Thomas A Mavrakanas
Thomas A Mavrakanas
Geneva University Hospitals
Switzerland

Can J Diabetes 2018 Apr 22;42(2):118-123. Epub 2017 Dec 22.

Division of Nephrology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. Electronic address:

Cardiovascular disease is the principal cause of morbidity and mortality in patients with diabetes mellitus. The incidence or progression of kidney disease is also common in these patients. Several clinical trials have established the efficacy of angiotensin receptor blockers for the prevention of adverse cardiovascular and renal outcomes in this population and are summarized in this review article. Head-to-head comparison of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors has shown similar cardioprotective and renoprotective properties of both medication classes. However, angiotensin receptor blockers have an improved safety profile with fewer episodes of cough and angioedema and may be the agent of choice in patients with diabetes and hypertension. Novel therapeutic strategies, such as those that include a mineralocorticoid receptor blocker or a selective sodium-glucose cotransporter type 2 inhibitor, may further protect patients with diabetes from cardiovascular and renal complications.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcjd.2017.11.006DOI Listing
April 2018
1 Read

Publication Analysis

Top Keywords

angiotensin receptor
20
receptor blockers
20
patients diabetes
12
cardiovascular renal
8
angiotensin-converting enzyme
8
enzyme inhibitors
8
receptor
6
blockers
5
angiotensin
5
properties medication
4
cardioprotective renoprotective
4
medication classes
4
inhibitors cardioprotective
4
renoprotective properties
4
blockers improved
4
improved safety
4
blockers angiotensin-converting
4
safety profile
4
classes angiotensin
4
summarized review
4

Similar Publications

The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus.

Can J Diabetes 2018 Apr 22;42(2):124-129. Epub 2017 Dec 22.

Leeds MRC Medical Bioinformatics Centre, University of Leeds, West Yorkshire, United Kingdom.

The renin angiotensin aldosterone system (RAAS) plays a central role in the pathophysiology of hypertension and vascular disease. Angiotensin-converting enzyme inhibitors (ACEi's) suppress angiotensin II (ANG II) concentrations, whereas angiotensin II type 1 (AT) receptor blockers (ARBs) block the binding of ANG II to AT receptors. ACEi's and ARBs are both effective antihypertensive agents and produce similar risk reductions for stroke, a blood pressure-dependent phenomenon. Read More

View Article
April 2018

Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.

PLoS Med 2016 Mar 8;13(3):e1001971. Epub 2016 Mar 8.

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Background: Medications aimed at inhibiting the renin-angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of RAS blockers on cardiovascular and renal outcomes in adults with diabetes.

Methods And Findings: Eligible trials were identified by electronic searches in PubMed/MEDLINE and the Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). Read More

View Article
March 2016

Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.

J Manag Care Pharm 2011 Oct;17(8 Suppl):S1-14

Duke Division of General Internal Medicine, Center for Health Services Research in Primary Care, Durham VA Medical Center, Durham, NC, USA.

Background: In 2007, the Agency for Healthcare Research and Quality (AHRQ) published a comparative effectiveness review (CER) on the benefits and risks of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) for treating essential hypertension in adults. The main findings indicated that the 2 classes of antihypertensive medications caused similar reductions in blood pressure, although higher rates of adverse events, especially cough, were reported by patients treated with ACEIs. In addition, the 2007 review indicated no treatment related differences in lipid levels, glycemic control, or progression of kidney disease among the agents. Read More

View Article
October 2011

Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.

Curr Opin Nephrol Hypertens 2004 May;13(3):319-24

Steno Diabetes Center, Gentofte, Denmark.

Purpose Of Review: Antihypertensive treatment has improved renal prognosis and survival in diabetic nephropathy. The present review summarizes the current status of blockade of the renin-angiotensin system in diabetic nephropathy. Since the current treatment strategies reduce, but do not prevent, the progression of kidney disease, the research focus is directed towards the potential renoprotective effects of dual blockade of the renin-angiotensin system using both angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Read More

View Article
May 2004